Press

MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

Dec 17 • 3 min read

Further to a news release of October 27, 2021, MYND Life Sciences Inc. (MYND) is pleased to announce it has successfully closed on the previously announced transaction to acquire the right, title and interest in and to the intellectual property rights for the use of psychedelics to treat Dementia (the “Acquired Assets“) from Cava Healthcare Inc. (“Cava“), a life…

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

Dec 16 • 3 min read

Entheon Biomedical Corp. (ENBI) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as well as nonclinical and clinical programs. US Provisional Patent Filed In furtherance of its…

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements

Dec 15 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Apeiron Investment Group, the family office of its Founder and Chairman, Christian Angermayer, has decided to voluntarily extend its lock-up for all of its pre-IPO common shares for another 24 months, subject to…

Atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

Dec 14 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is a stock market index made up of securities of Nasdaq-listed…

PharmaTher Announces Positive Research Results for LSD Microneedle Patch

Dec 14 • 3 min read

PharmaTher Holdings Ltd. (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle patch for the intradermal delivery of psychedelics, in delivering lysergic acid diethylamide. These results provide support to file for an IND application with the FDA to conduct…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441